The IPO queue adds 5 more biotechs hoping to ring in 2021 by blitzing Nasdaq
Following a record year for IPOs — in terms of both proceeds and count — there’s already a long lineup of biotechs ready to jump onto Nasdaq in the new year. The companies are likely looking for much higher raises than they initially projected on their S-1s. Now it’s time to see if investors are still hungry for another round of biotech stocks.
Sana helped set the pace early on, as its founders look to divvy up a fortune from their IPO. And late last week 5 more biotechs crowded in, looking to pick up the pace where 2020 left off. Here they are:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.